CA2995430C - Compounds and methods for inhibiting jak - Google Patents
Compounds and methods for inhibiting jak Download PDFInfo
- Publication number
- CA2995430C CA2995430C CA2995430A CA2995430A CA2995430C CA 2995430 C CA2995430 C CA 2995430C CA 2995430 A CA2995430 A CA 2995430A CA 2995430 A CA2995430 A CA 2995430A CA 2995430 C CA2995430 C CA 2995430C
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- pyrazol
- methoxy
- amino
- propanamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562232629P | 2015-09-25 | 2015-09-25 | |
| US62/232,629 | 2015-09-25 | ||
| PCT/EP2016/072616 WO2017050938A1 (en) | 2015-09-25 | 2016-09-22 | Compounds and methods for inhibiting jak |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2995430A1 CA2995430A1 (en) | 2017-03-30 |
| CA2995430C true CA2995430C (en) | 2023-07-11 |
Family
ID=56979589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2995430A Active CA2995430C (en) | 2015-09-25 | 2016-09-22 | Compounds and methods for inhibiting jak |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US9714236B2 (enExample) |
| EP (2) | EP3353168B1 (enExample) |
| JP (1) | JP6767491B2 (enExample) |
| KR (2) | KR102774784B1 (enExample) |
| CN (4) | CN111606893B (enExample) |
| AR (1) | AR106138A1 (enExample) |
| AU (1) | AU2016328764B2 (enExample) |
| BR (1) | BR112018005833B1 (enExample) |
| CA (1) | CA2995430C (enExample) |
| DK (1) | DK3353168T3 (enExample) |
| ES (1) | ES2956642T3 (enExample) |
| MX (1) | MX375724B (enExample) |
| PT (1) | PT3353168T (enExample) |
| RU (1) | RU2760359C2 (enExample) |
| TW (1) | TWI740843B (enExample) |
| WO (1) | WO2017050938A1 (enExample) |
| ZA (1) | ZA201800782B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102774784B1 (ko) * | 2015-09-25 | 2025-02-27 | 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 | Jak를 억제하기 위한 화합물 및 방법 |
| CN109311858B (zh) | 2016-05-26 | 2021-12-03 | 里科瑞尔姆Ip控股有限责任公司 | Egfr抑制剂化合物 |
| PE20191108A1 (es) | 2017-01-17 | 2019-08-26 | Astrazeneca Ab | Inhibidores selectivos de jak1 |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| US11149029B2 (en) * | 2018-07-18 | 2021-10-19 | Astrazeneca Ab | Salts of IJAK inhibitors and methods of using the same |
| EP3854793A4 (en) * | 2018-09-21 | 2022-06-01 | Shanghai Ennovabio Pharmaceuticals Co., Ltd. | AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY |
| KR102195348B1 (ko) * | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| AU2020258619C1 (en) * | 2019-04-19 | 2026-01-29 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | JAK1 selective kinase inhibitor |
| CN110627775B (zh) * | 2019-10-24 | 2026-01-30 | 特科罗生物科技(成都)有限公司 | 一种小分子化合物 |
| CN111961037B (zh) * | 2020-09-17 | 2021-09-21 | 嘉兴特科罗生物科技有限公司 | 一种作为jak激酶抑制剂的药物化合物 |
| WO2022111499A1 (zh) | 2020-11-26 | 2022-06-02 | 深圳铂立健医药有限公司 | 一种酰胺化合物、药物组合物及其应用 |
| EP4297873A1 (en) * | 2021-02-26 | 2024-01-03 | Tyra Biosciences, Inc. | Aminopyrimidine compounds and methods of their use |
| US12390451B2 (en) | 2021-03-11 | 2025-08-19 | Janssen Pharmaceutica Nv | Small molecule inhibitor of the JAK family of kinases |
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
| WO2025230951A1 (en) * | 2024-04-29 | 2025-11-06 | Icahn School Of Medicine At Mount Sinai | Method of treating adenoid cystic carcinoma |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2364340T3 (es) | 2004-03-30 | 2011-08-31 | Vertex Pharmaceuticals Incorporated | Azaindoles útiles como inhibidores de jak y otras proteína quinasas. |
| GB0500492D0 (en) * | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
| BRPI0618011A2 (pt) | 2005-10-28 | 2011-08-16 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente |
| EA200870217A1 (ru) * | 2006-01-30 | 2009-02-27 | Экселиксис, Инк. | 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции |
| JP5208123B2 (ja) * | 2006-12-08 | 2013-06-12 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| KR101705158B1 (ko) * | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
| NZ596479A (en) | 2009-05-22 | 2014-01-31 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| US20130225615A1 (en) * | 2010-09-01 | 2013-08-29 | Ambit Biosciences Corporation | 2-cycloquinazoline derivatives and methods of use thereof |
| US9198911B2 (en) | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
| AU2011328237A1 (en) * | 2010-11-09 | 2013-05-23 | Cellzome Limited | Pyridine compounds and aza analogues thereof as TYK2 inhibitors |
| CA2818542A1 (en) * | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| WO2012116247A1 (en) | 2011-02-25 | 2012-08-30 | Synta Pharmaceuticals Corp. | Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers |
| US8691807B2 (en) * | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
| DK2830662T3 (da) | 2012-03-29 | 2019-01-02 | Univ Columbia | Fremgangsmåder til behandlng af hårtabsforstyrrelser |
| KR102774784B1 (ko) * | 2015-09-25 | 2025-02-27 | 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 | Jak를 억제하기 위한 화합물 및 방법 |
-
2016
- 2016-09-22 KR KR1020187008186A patent/KR102774784B1/ko active Active
- 2016-09-22 MX MX2018003590A patent/MX375724B/es active IP Right Grant
- 2016-09-22 US US15/272,554 patent/US9714236B2/en active Active
- 2016-09-22 CA CA2995430A patent/CA2995430C/en active Active
- 2016-09-22 PT PT167700319T patent/PT3353168T/pt unknown
- 2016-09-22 DK DK16770031.9T patent/DK3353168T3/da active
- 2016-09-22 WO PCT/EP2016/072616 patent/WO2017050938A1/en not_active Ceased
- 2016-09-22 CN CN202010629290.1A patent/CN111606893B/zh active Active
- 2016-09-22 RU RU2018112993A patent/RU2760359C2/ru active
- 2016-09-22 JP JP2018535238A patent/JP6767491B2/ja active Active
- 2016-09-22 CN CN202010626114.2A patent/CN111848586B/zh active Active
- 2016-09-22 CN CN202010629286.5A patent/CN111646980B/zh active Active
- 2016-09-22 KR KR1020257006096A patent/KR20250035597A/ko active Pending
- 2016-09-22 CN CN201680055491.7A patent/CN108368091B/zh active Active
- 2016-09-22 BR BR112018005833-5A patent/BR112018005833B1/pt active IP Right Grant
- 2016-09-22 EP EP16770031.9A patent/EP3353168B1/en active Active
- 2016-09-22 AU AU2016328764A patent/AU2016328764B2/en active Active
- 2016-09-22 ES ES16770031T patent/ES2956642T3/es active Active
- 2016-09-22 EP EP23150992.8A patent/EP4219482A1/en active Pending
- 2016-09-23 AR ARP160102919A patent/AR106138A1/es active IP Right Grant
- 2016-09-23 TW TW105130891A patent/TWI740843B/zh active
-
2017
- 2017-05-22 US US15/601,324 patent/US10167276B2/en active Active
-
2018
- 2018-02-06 ZA ZA2018/00782A patent/ZA201800782B/en unknown
- 2018-11-20 US US16/196,038 patent/US10654835B2/en active Active
-
2020
- 2020-04-28 US US16/860,169 patent/US11247983B2/en active Active
-
2021
- 2021-12-28 US US17/563,913 patent/US12319670B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12319670B2 (en) | Compounds and methods for inhibiting JAK | |
| EP2498607B1 (en) | Kinase inhibitors | |
| JP7418353B2 (ja) | トリアゾロピリミジン化合物およびがんの処置におけるそれらの使用 | |
| US20240374606A1 (en) | Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer | |
| AU2004283093A1 (en) | Compounds and compositions as protein kinase inhibitors | |
| HK40096832A (en) | Compounds and methods for inhibiting jak | |
| HK40035295A (en) | Compounds and methods for inhibiting jak | |
| HK40026896A (en) | Compounds and methods for inhibiting jak | |
| HK40026896B (en) | Compounds and methods for inhibiting jak | |
| HK40035295B (en) | Compounds and methods for inhibiting jak | |
| HK40026768B (en) | Compounds and methods for inhibiting jak | |
| HK40026768A (en) | Compounds and methods for inhibiting jak | |
| HK1259422B (en) | Compounds and methods for inhibiting jak | |
| WO2022070068A1 (en) | Dihydroorotate dehydrogenase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210817 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240904 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240904 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240904 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250902 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250902 |